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Abstract 
Objective Evidence suggests that aberrant function of innate lymphoid 
cells (ILC), whose functional and transcriptional profile overlap with T 
helper (Th) cell subsets, contribute to immune-mediated pathologies. To 
date, analysis of Juvenile Idiopathic Arthritis (JIA) immune-pathology has 
concentrated on the contribution of CD4+ T-cells; we have previously 
identified an expansion of Th17 cells within the synovial fluid (SF) of JIA 
patients. Here, we extend this analysis to investigate a role for ILC and 
other IL-17 producing T-cell subsets. 
Methods ILC and CD3+ T-cell subsets were defined in peripheral blood 
mononuclear cells (PBMC) (healthy adult, healthy child and JIA patients) 
and JIA SF mononuclear cells (SFMC) using flow cytometry. Defined 
subsets in SFMC were correlated with clinical measures including 
physician’s visual analogue scale (VAS), active joint count and erythrocyte 
sedimentation rate (ESR). Transcription factor and cytokine profiles of 
sorted ILC were assessed by qPCR.  
Results Group 1 ILC (ILC1), NKp44-group 3 ILC (NCR-ILC3) and 
NKp44+group 3 ILC (NCR+ILC3) were enriched in the JIA-SFMC 
compared to PBMC, which corresponded with an increase in transcripts 
for TBX21, IFNG and IL17A. Of the ILC subsets, NCR-ILC3 frequency in 
JIA-SFMC displayed the strongest positive association with clinical 
measures which was mirrored by an expansion in IL-17A+CD4+, IL-
17A+CD8+ and IL-17A+γδ T-cells. 
Conclusion We demonstrate that the strength of the IL-17A signature in 
JIA-SFMC is determined by multiple lymphoid cell-types, including NCR-
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ILC3, IL-17A+CD4+, IL-17A+CD8+ and IL-17A+γδ T-cells. These 
observations may have important implications for the development of 
stratified therapeutics. 
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Introduction 
Juvenile idiopathic arthritis (JIA), the most common rheumatic disease in 
childhood, is characterised by joint inflammation lasting longer than 6 
weeks [1]. The umbrella term JIA encompasses many subtypes including  
oligo-articular-JIA (Oligo-JIA), poly-articular-JIA (poly-JIA), enthesitis-
related arthritis (ERA), psoriatic-arthritis (PsA) and systemic-JIA [1]. Apart 
from systemic-JIA, which has a distinct pathogenesis, studies suggest that 
synovitis in a proportion of JIA cases is linked to IL-23/IL-17A cytokine axis 
[2]. To date, the IL-17A signature within JIA synovial fluid mononuclear 
cells (SFMC) has been delineated only in CD4+ T helper (Th) cells. 
Emerging evidence indicates that innate lymphoid cells (ILC), the 
most recently discovered members of the lymphoid family, have critical  
roles in immunity, tissue development and remodeling [3]. Similarly to Th 
cells, CD127+ helper ILCs can be divided into distinct groups based upon 
their functional and transcriptional profile: Th1-equivalent Group 1 ILC 
(ILC1) express TBX21 (T-BET) and produce IFNγ,  Th2-equivalent group 2 
ILC (ILC2) express GATA3 and produce IL-13, Th17-equivalent natural 
cytotoxicity receptor (NCR)-group 3 ILC (NCR-ILC3) express RORC2 and 
produce IL-17A/IL-22 and Th22-equivalent NCR+ILC3 NCR+ILC3  
express RORC2, AHR and only produce IL-22 [3]. From a clinical 
viewpoint, chronic ILC activation has been associated with a wide-range of 
inflammatory disorders [3]. To date, there is no data regarding ILC 
phenotype/function in childhood arthritides.  
Herein, we demonstrate that ILC1, NCR-ILC3, NCR+ILC3 subsets 
are expanded within JIA-SFMC compared to adult healthy controls, child 
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healthy controls, and JIA peripheral blood mononuclear cells (PBMC) but 
that NCR-ILC3 show the strongest association with multiple measures of 
clinical severity. Notably, the increase in NCR-ILC3 within JIA-SFMC was 
accompanied with an increase in IL-17 producing CD4+, CD8+ and γδ T-
cells. These data suggest that the IL-17 signature previously observed in 
JIA-SFMC CD4+ T-cells may extend to the ILC compartment and other T-
cell subsets. 
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Patients and methods 
Human Samples 
Peripheral blood (PB) from healthy adult (aHC), child controls (cHC) and 
JIA patients, and synovial fluid (SF) from JIA patients were obtained with 
fully informed and age-appropriate consent as approved by the London-
Bloomsbury Research Ethics Committee (ref: 95RU04) in accordance with 
the Declaration of Helsinki. Clinical subtypes of JIA were defined 
according to International League of Associations for Rheumatology 
criteria (ILAR) [1]. Clinical and demographical data are shown in 
Supplementary Table 1. PB and SF mononuclear cells (PBMC and SFMC) 
were prepared by density gradient centrifugation. Before processing, SF 
samples were treated with Hyaluronidase (10U/ml; Sigma-Aldrich) for 30 
mins at 37°C. 
 
Flow Cytometry, Image Stream and Cell Sorting 
Flow cytometry was performed using directly conjugated monoclonal 
antibodies (listed in Supplementary Table 2) as described [2]. Dead cells 
were excluded using a live/dead discrimination dye (Thermo Scientific). 
ILC were defined as cells within the lymphocyte gate that were single 
cells, lineage negative (CD1a, CD3, CD11c, CD14, CD16, CD19, CD34, 
CD94, CD123, BDCA2, FcεRIα, αβTCR and γδTCR), CD45+, CD127+ 
and CD161+. ILC subpopulations were defined according to phenotype: 
ILC1 (CRTH2-cKit-) ILC2 (CRTH2+) NCR-ILC3 (CRTH2-cKit+NKp44-) 
and NCR+ILC3 (CRTH2-cKit+NKp44+) [4]. Data were acquired on LSRII 
flow cytometer (BD) and analysed using FlowJo software version 10.1 
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(TreeStar Inc.).  For Image stream analysis, ILC were stained and 
analysed on Amnis ImagestreamX Mark II (Merck Millipore). For cell 
sorting, ILC were stained as above and sorted on a FACSAriaIII (BD).  
 
RNA extraction and qRT-PCR 
RNA was routinely extracted from sorted (~50,000-100,000) ILCs using 
the Arcturus Picopure RNA isolation kit (ThermoFisher Scientific) and 
cDNA synthesized (iScript DNA kit;Bio-rad) according to manufacturer’s 
instructions. cDNA was amplified using SYBR Green Mastermix (Bio-rad) 
with custom primers for AHR, RORC2, GATA3, TBX21, IL17A, IL22, IL13 
and IFNG (Life Technologies); primer sequences are listed in 
Supplementary Table 3. For each sample, transcript quantity was 
normalized to β−actin (ACTB) expression. 
 
Statistical analysis  
Statistical analysis was performed using Prism 5.03 (Graphpad). In bar 
charts data represent standard error of the mean. For comparison of two 
groups Mann-Whitney U Tests were used. For multiple comparison 
testing, Kruskal-Wallis tests with Dunn’s multiple comparison tests were 
performed. P values of less than 0.05 were considered significant and 
indicated on graphs. Spearman’s correlation with Bonferroni’s correction 
for multiple testing was used for correlation analyses, uncorrected p 
values and the adjusted Bonferroni alpha cut-off are reported in 
Supplementary Table 4.  
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Results 
Expansion of ILC1, NCR-ILC3 and NCR+ILC3 in JIA-SFMC.  
ILC (lineage-CD45+CD127+CD161+), were enumerated within PBMC and 
SFMC of JIA patients and PBMC of adult (aHC) and child (cHC) healthy 
controls (Figure 1A and B). The ILC population was small as a proportion 
of all live mononuclear cells in both compartments (0.005-0.5% of total live 
mononuclear cells) consistent with other reports in human adult PBMC [4].  
There were no significant differences in the proportion of ILC within all 
mononuclear cell populations tested (Figure 1A and B).  
Next, we determined whether there were differences in ILC 
subsets, as a proportion of total ILC, in PBMC versus SFMC. ILC subsets 
were identified as ILC1 (CRTH2-cKit-); ILC2 (CRTH2+); and ILC3 
(CRTH2-cKit+), which were divided into NCR+ and NCR- subgroups 
according to expression of NKp44. Given the low frequency of ILC 
populations, ImageStream analysis was used to confirm that both PBMC 
and SFMC ILC subtypes were lymphoid in morphology and that antibody 
staining was localized to the membrane prior to analysis (Supplementary 
Fig. 1A). Assessment of ILC subset frequency showed that ILC1 cells 
were significantly enriched as a proportion of total ILC in JIA-SFMC 
compared to JIA-PBMC, aHC and cHC-PBMC (Figure 1C and D). Further 
analyses revealed that the largest differences in ILC1 frequency was 
observed between PBMC and SFMC from patients with oligo-JIA (Figure 
1D) complementing historic data demonstrating that T-cells from oligo-JIA 
patients produce a significant amount of IFNγ [5]. ILC2, which have been 
implicated in the resolution of chronic joint inflammation by supporting 
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Treg function [6], were significantly lower in SFMC compared to PBMC 
from patients or controls, with both oligo-JIA and ERA displaying a 
significant difference between SFMC and aHC-PBMC (Figure 1C and E). 
These differences may reflect the larger number of ERA-JIA and oligo-JIA 
patients analysed in our cohort. 
Within the ILC3 compartment, the proportion of NCR-ILC3 was 
significantly higher in SFMC compared to aHC-PBMC or JIA-PBMC and 
this effect was observed in all JIA subtypes (Figure C and 1F). There was 
a significant enrichment of NCR+ILC3, which were present at very low 
frequency in PBMC from patients and controls, in SFMC from all JIA 
subtypes compared to aHC (Figure 1C, F and G). No differences were 
observed in the frequency of ILC subsets amongst PBMC or SFMC 
between all JIA subtypes analysed. 
 
 
Transcriptional profile of ILC within JIA-SFMC is altered compared to 
ILC within PBMC  
Increasing evidence indicates that ILC1, ILC2, NCR-ILC3 and NCR+ILC3 
express specific transcription factors and cytokine profiles that parallel 
Th1, Th2, Th17, Th22 cells respectively [3, 4]. Accordingly, we next 
assessed whether variation in the frequency of ILC subsets observed in 
PBMC versus SFMC was associated with an altered transcriptional profile. 
Gene expression analysis of transcription factors (TBX21, GATA3, 
RORC2, AHR) and cytokines (IFNG, IL13, IL17A, IL22) by qPCR in SFMC 
ILC relative to aHC-PBMC ILC demonstrated that there was a significant 
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increase in type-1 associated TBX21 and IFNG and a significant decrease 
in type-2 associated GATA3 and IL13 mirroring the changes in subset 
frequency we had observed by flow cytometry (Figure 2A and B). Analysis 
of transcription factors and cytokines associated with ILC3 subsets 
demonstrated a significant increase in the relative expression of IL17 and 
a trend for an increase in RORC2, AHR and IL22 although the expression 
varied between JIA-SFMC samples (Figure C and D). Due to the small 
amount of blood taken from children we were unable to isolate sufficient 
ILC from cHC or JIA-PBMC to perform qPCR analysis.  
 
Changes in ILC subset frequency within the synovial fluid of patients 
with JIA are associated with disease severity 
As the ILC subset frequency and transcriptional profile was altered in JIA-
SFMC, we next investigated whether these changes were associated with 
clinical measure of disease severity. Physician’s visual analogue scale 
(VAS), active joint count, and erythrocyte sedimentation rate (ESR) were 
correlated with the proportion of ILC1, NCR+ILC3 or NCR-ILC3 within total 
ILC within SFMCs. ILC2 were not included in these analyses due their 
paucity within SFMC. This exploratory analysis showed promising trends 
that the frequency of ILC1, NCR+ILC3 and NCR-ILC3 subsets were 
associated with disease severity (Figure 2E and Supplementary Table 4). 
Notably, whilst ILC1 and NCR-ILC3 positively associated with an increase 
in physician’s VAS, there was a negative correlation between physician’s 
VAS and NCR+ILC3. One potential hypothesis is that NCR+ILC3 may also 
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be important in the resolution of joint inflammation in JIA, similarly to 
observations previously reported in the inflamed gastrointestinal tract in 
ankylosing spondylitis [7]. Potential correlation between ILC subset 
frequency and active joint count or ESR was next assessed. A positive 
association between NCR-ILC3 cells and active joint count and a weak 
association between NCR-ILC3 and ESR was observed (Figure 2F-G and 
Supplementary Table 4). No association between ILC1 and NCR+ILC3 
and active joint count or ESR was seen.  Markedly, no differences in the 
frequency of SFMC ILC1, NCR-ILC3 and NCR+ILC3 were observed 
between treatment-naïve versus patients on methotrexate (Supplementary 
Figure 1B-D). 
 
Expansion of NCR-ILC3 in synovial fluid of JIA patients is associated 
with an increase in IL-17A producing CD4+ T-cells, CD8+ T-cell and γδ 
T-cells 
Herein, we have demonstrated that ILC subset frequency, transcriptional 
profile is altered in SFMC isolated from JIA and that of the ILC subsets 
identified within the JIA-SFMC an expansion of NCR-ILC3 has the 
strongest association with multiple measures of clinical severity. NCR-
ILC3 can be characterized by the expression of RORC and IL-17A, 
similarly to Th17 cells, and can be found expanded in IL-17A driven 
pathologies [8]. Taken together, these data suggest that the IL-17A CD4+ 
T-cell signature we have previously described in JIA SF may extend to 
other cell-types including ILC [2]. To investigate this, we quantified other 
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potential IL-17A producing cell types; this included CD4+ T-cells, CD8+ T-
cells, γδ T-cells.  As previously described [2], we found higher percentages 
of IL-17A+CD4+ cells within JIA-SFMC compared to healthy and JIA-
PBMC (Figure 3A). Analysis of IL-17A+CD8+ and IL-17A+CD4-CD8- (of 
which ~80% were γδ T-cells, data not shown) cells established that there 
was also a significantly higher percentage of IL-17A+CD8+ and a trend for 
an increase in IL-17A+CD4-CD8- in JIA-SFMC compared to aHC-PBMC 
and JIA-PBMC (Figure 3B and C). No significant differences were seen 
between aHC, cHC and JIA-PBMC. Unlike the enrichment of NCR-ILC3 
within the SFMC of all subtypes of JIA (Figure 1F), there were significant 
differences in the frequency of IL-17A-producing T-cells between JIA 
subtypes. For example, in agreement with published reports 
demonstrating a strong IL-17A signature in ERA, we found an increase in 
IL-17A-producing CD4+, CD8+ and CD4-CD8- T-cells in SFMCs isolated 
from ERA patients (Figure 3A-C) [9].  It is worth highlighting however that 
there was a proportion of patients that displayed a strong IL17A signature 
regardless of subtype.  
To assess whether the IL-17A T-cell-signature was associated with 
an expansion of NCR-ILC3, a correlation analysis was performed between 
the various synovial subpopulations analysed. Positive correlations were 
observed in SFMC between NCR-ILC3 as a proportion of total live cells 
and IL-17A-positive cells in the CD4+ and CD8+ T-cell compartments 
(Figure 3D and E and Supplementary Figure 4). A weak potential 
association with IL-17A+CD4-CD8- T-cells was also observed (Figure 3F 
and Supplementary Figure 4). These data demonstrate that the expansion 
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of NCR-ILC3 is concomitant with the expansion of IL-17A producing T-
cells within JIA-SFMC; indicating that the cell specific contribution to the 
IL-17A milieu in JIA-SFMC may be a key determinant of clinical outcome. 
Of note, correlation between the percentage of IL-17+CD4+, IL-17+CD8+ 
and IL-17+CD4-CD8 with physician’s VAS, active joint count and ESR 
demonstrated that of the T-cell subsets, CD4+ T-cells had the strongest 
association with physicians VAS (Supplementary Figure 2 and 
Supplementary Figure 4). However unlike NCR-ILC3, the percentage of 
IL-17A+ T-cell subsets did not have any association with active joint count 
or ESR.  
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DISCUSSION 
 Recent investigation into ILC biology and function has led to an 
appreciation of their role in tissue/immune homeostasis and their 
contribution to immunopathology. However, this is the first study to 
investigate whether ILC phenotype and function is altered in JIA. We 
demonstrate that ILC1, NCR-ILC3 and NCR+ILC3 are expanded within 
JIA-SFMCs. Most interestingly, NCR-ILC3, the innate equivalent to Th17 
cells [10], exhibit a positive association with disease severity and with an 
increase in multiple IL-17A producing T-cell subsets. Future studies are 
needed to confirm our hypothesis that the strength of the IL-17A signature 
within JIA SFMC is shared amongst multiple cell-types. 
Both human studies and animal models support a central role for 
IL-17A in JIA pathogenesis. For example, IL-17A-deficient mice are 
resistant to the induction of collagen-induced arthritis (CIA) [11] and levels 
of IL-17A are known to be significantly higher in the JIA SF [9]. However, 
the relative contribution of different cell-types to IL-17A production within 
the inflamed joint remains relatively unexplored. Our data show that both 
innate, namely NCR-ILC3, and adaptive lymphoid cells, namely T-cells 
(CD4+, CD8+ and γδ), may contribute to IL-17A production at the 
inflammatory site. Further work is needed to unravel the mechanisms that 
underlie the preferential accumulation of multiple IL-17A-producing cell-
types with JIA-SFMC.  One possible explanation is that the presence of 
high levels of IL-1β, IL-23 and IL-6 within the synovial environment of JIA 
[12] creates an “IL-17A-skewing” micro-environment that induces the 
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differentiation of Th17 cells and ILC3 [3, 13]. Future studies using single 
cell RNA sequencing will aid in defining detailed functional and 
transcriptional heterogeneity in SFMC-ILC as recently reported for human 
tonsils [14]. At present our data demonstrate the presence of an 
inflammatory type-1 and type-17 transcriptional signature in total SFMC-
ILC but not which ILC1/ILC3 subset is responsible for this transcriptional 
signature. This is especially pertinent as it is not yet known how the 
inflammatory environment of the arthritic joint alters the plasticity of 
ILC1/ILC3 subsets. 
Despite success of JIA treatment with TNFα- and IL-6-blockade, a 
group of patients remain unresponsive to treatment. Here, our exploratory 
analysis demonstrate that disease severity could potentially be associated 
with an increase in multiple IL-17 producing lymphoid cell-types. This 
suggests that IL-17A targeting treatments could be efficacious in a 
significant proportion of JIA patients (who may fall into several of the 
current clinically defined subtypes). This notion is further supported by 
recent evidence showing that Secukinumab, a monoclonal antibody 
against IL-17A, is effective in the treatment of ankylosing spondylitis, 
another IL-17A-driven autoimmune disease [15]. Our observations raise 
the possibility that patients may be better stratified for treatment with 
biologics based on immune-phenotype rather than by previously ascribed 
clinical categories.  It is now essential to gain a whole-system view of IL-
17A biology in order to design novel therapeutic strategies.  
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Figure Legends 
Figure 1. ILC1, NCR-ILC3 and NCR+ILC3 are expanded in the SF of 
patients with JIA. (A) Representative flow cytometry plots and (B) 
summary scatter plots with bar charts showing the frequency of total ILC 
(defined as Lineage-CD127+CD161+) within total CD45+ live cells in adult 
healthy (aHC, n=12) PBMC, child healthy (cHC, n=4) PBMC, JIA-PBMC 
(total n=15, ERA n=8, oligo-JIA n=4, poly-JIA n=2, PsA n=3) and JIA- 
SFMC (total n=38, ERA n=17, oligo-JIA n=13, poly-JIA n=3, PsA n=5). (C) 
Representative flow cytometry plots and (D-G) summary scatter plots with 
bar charts showing the frequency of (D) ILC1 (defined as Lineage-
CD127+CD161+cKit-CRTH2-), (E) ILC2 (defined as Lineage-
CD127+CD161+CRTH2+), (F) NCR-ILC3 (defined as Lineage-
CD127+CD161+cKit+CRTH2-NKp44-) and (G) NCR+ILC3 (defined as 
Lineage-CD127+CD161+cKit+CRTH2-NKp44+) within total ILC in adult 
healthy (aHC, n=12) PBMC, child healthy (cHC, n=4) PBMC, JIA-PBMC 
(total n=15, ERA n=8, oligo-JIA n=4, poly-JIA n=2, PsA n=3) and JIA-
SFMC (total n=38, ERA n=17, oligo-JIA n=13, poly-JIA n=3, PsA n=5). 
Statistical analysis carried out by Kruskal Wallis with Dunn’s multiple 
comparison tests. Bar charts represent mean ± SE.  
Figure 2. Changes in ILC subset frequency within total SFMC ILCs is 
associated with changes in transcriptional profile in and clinical 
severity. Summary scatter plots with bar charts showing the relative 
expression of (A) TBX21 and IFNG, (B) GATA3 and IL13, (C) RORC2 and 
IL17A, (D) AHR and IL22 in SFMC (n=5) versus PBMC (n=5) as measured 
by qPCR. Statistical analysis carried out by Mann-Whitney U Tests. Bar 
charts represent mean ± SE. (E-G) Scatter plots showing relationship 
between (E) physician’s VAS (n=24), (F) active joints (n=27), (G) ESR 
(n=18) and the frequency of ILC1, NCR-ILC3 and NCR+ILC3 within total 
live cells in JIA-SFMC at time of sample. Statistical analysis carried out by 
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Spearman correlation analysis with Bonferroni’s correction for multiple 
testing.  
Figure 3. IL-17A-producing CD4+, CD8+ and γδ T-cells in JIA SF. (A-
C) Representative flow cytometry plots and summary scatter plots with bar 
charts showing the frequency of IL-17A+ cells within (A) CD4+ cells, (B) 
CD8+ T-cells and CD4-CD8- in CD3+ gated live cells in aHC-PBMC 
(n=12), child healthy cHC (n=6) PBMC, JIA-PBMC (total n=25, ERA n=13, 
oligo-JIA n=4, poly-JIA n=6, PsA n=3) and JIA-SFMC (total n=41, ERA 
n=17, oligo-JIA n=8, poly-JIA n=6, PsA n=10). Statistical analysis carried 
out by Kruskal Wallis with Dunn’s multiple comparison tests. Bar charts 
represent mean ± SE. (D-F) Scatter plots showing relationship between 
the frequency of (D) IL-17A+CD4+ T-cells, (E) IL-17A+CD8+ T-cells and 
(F) IL-17A+CD4-CD8- T- cells with percentage of NCR-ILC3 within total 
live cells in JIA-SFMC (n=16). Statistical analysis carried out by Spearman 
correlation analysis with Bonferroni’s correction for multiple testing.  
Supplementary Figure 1. SFMC-ILC subsets have the same 
morphology as PBMC-ILC subsets and their frequency are not 
altered by treatment status. ILC subsets were identified according to 
fluorescence of subset specific protein expression by analysis of individual 
cell images as shown using image stream. Representative images of ILC 
subsets from (A) PBMC and (B) SFMC from JIA patients. All ILC detected 
had a characteristically dense single nuclei, a thin halo of perinuclear 
cytoplasm, were approx 7µm and had cell markers restricted to the cell 
surface. Left hand panel (grey) shows the brightfield image. Summary 
scatter plots with bar charts showing the frequency of (C) ILC1, (B) NCR-
ILC3 and (E) NCR+ILC3 with JIA-SFMC of treatment naïve JIA patients 
9n=14) and patients on methotrexate (n=17). Bar charts represent mean ± 
SE.  
Supplementary Figure 2. IL-17A+ T cell subsets can be associated 
with clinical measure of disease severity. Scatter plots showing 
relationship between (A) physician’s VAS (n=15), (B) active joints (n=21) 
and (C) ESR (n=17) and the frequency of IL-17+CD4+ T cells, IL-
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17+CD8+ T cells and IL-17+CD4-CD8- T cells within JIA-SFMC. Statistical 
analysis carried out by Spearman correlation analysis with Bonferroni’s 
correction for multiple testing.  
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FIGURE 1: ILC1, NCR-ILC3 and NCR+ILC3 are expanded in the SF of patients with JIA. (A) Representative 
flow cytometry plots and (B) summary scatter plots with bar charts showing the frequency of total ILC 
(defined as Lineage-CD127+CD161+) within total CD45+ live cells in adult healthy (aHC, n=12) PBMC, child 
healthy (cHC, n=4) PBMC, JIA-PBMC (total n=15, ERA n=8 oligo-JIA n=4, poly-JIA n=2, PsA n=3) and JIA- 
SFMC (total n=38, ERA n=17 oligo-JIA n=13, poly-JIA n=3, PsA n=5). (C) Representative flow cytometry 
plots and (D-G) summary scatter plots with bar charts showing the frequency of (D) ILC1 (defined as 
Lineage-CD127+CD161+cKit-CRTH2-), (E) ILC2 (defined as Lineage-CD127+CD161+CRTH2+), (F) NCR- 
ILC3 (defined as Lineage-CD127+CD161+cKit+CRTH2-NKp44-) and (G) NCR+ILC3 (defined as Lineage- 
CD127+CD161+cKit+CRTH2-NKp44+) within total ILC in adult healthy (aHC, n=12) PBMC, child healthy 
(cHC, n=4) PBMC, JIA-PBMC (total n=15, ERA n=8 oligo-JIA n=4, poly-JIA n=2, PsA n=3) and JIA-SFMC 
(total n=38, ERA n=17 oligo-JIA n=13, poly-JIA n=3, PsA n=5). Statistical analysis carried out by Kruskal 
Wallis with Dunn’s multiple comparison tests. Bar charts represent mean ± SE.  
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FIGURE 2: Changes in ILC subset frequency within total SFMC ILCs is associated with changes in 
transcriptional profile in and clinical severity. Summary scatter plots with bar charts showing the relative 
expression of (A) TBX21 and IFNG, (B) GATA-3 and IL-13, (C) RORC2 and IL-17A, (D) AhR and IL-22 in 
SFMC (n=5) versus PBMC (n=5) as measured by qPCR. Statistical analysis carried out by Mann-Whitney U 
Tests. Bar charts represent mean ± SE. (E-G) Scatter plots showing relationship between (E) physician’s 
VAS (n=24), (F) active joints (n=27), (G) ESR (n=18) and the frequency of ILC1, NCR-ILC3 and NCR+ILC3 
within total live cells in JIA-SFMC at time of sample. Statistical analysis carried out by Spearman correlation 
analysis with Bonferroni’s correction for multiple testing.  
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FIGURE 3: IL-17A-producing CD4+, CD8+ and γδ T-cells in JIA SF. (A-C) Representative flow cytometry 
plots and summary scatter plots with bar charts showing the frequency of IL-17A+ cells within (A) CD4+ 
cells, (B) CD8+ T-cells and CD4-CD8- in CD3+ gated live cells in aHC-PBMC (n=12), child healthy cHC 
(n=6) PBMC, JIA-PBMC (total n=25, ERA n=13, oligo-JIA n=4, poly-JIA n=6, PsA n=3) and JIA-SFMC (total 
n=41, ERA n=17, oligo-JIA n=8, poly-JIA n=6, PsA n=10). Statistical analysis carried out by Kruskal Wallis 
with Dunn’s multiple comparison tests. Bar charts represent mean ± SE. (D-F) Scatter plots showing 
relationship between the frequency of (D) IL-17A+CD4+ T-cells, (E) IL-17A+CD8+ T-cells and (F) IL-
17A+CD4-CD8- T- cells with percentage of NCR-ILC3 within total live cells in JIA-SFMC (n=16). Statistical 
analysis carried out by Spearman correlation analysis with Bonferroni’s correction for multiple testing.  
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SUPPLEMENTARY FIGURE 1: SFMC-ILC subsets have the same morphology as PBMC-ILC subsets and their 
frequency are not altered by treatment status. ILC subsets were identified according to fluorescence of 
subset specific protein expression by analysis of individual cell images as shown using image stream. 
Representative images of ILC subsets from (A) PBMC and (B) SFMC from JIA patients. All ILC detected had a 
characteristically dense single nuclei, a thin halo of perinuclear cytoplasm, were approx 7µm and had cell 
markers restricted to the cell surface. Left hand panel (grey) shows the brightfield image. Summary scatter 
plots with bar charts showing the frequency of (C) ILC1, (B) NCR-ILC3 and (E) NCR+ILC3 with JIA-SFMC of 
treatment naïve JIA patients 9n=14) and patients on methotrexate (n=17). Bar charts represent mean ± 
SE.  
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SUPPLEMENTARY FIGURE 2: IL-17A+ T cell subsets can be associated with clinical measure of disease 
severity. Scatter plots showing relationship between (A) physician’s VAS (n=15), (B) active joints (n=21) 
and (C) ESR (n=17) and the frequency of IL-17+CD4+ T cells, IL-17+CD8+ T cells and IL-17+CD4-CD8- T 
cells within JIA-SFMC. Statistical analysis carried out by Spearman correlation analysis with Bonferroni’s 
correction for multiple testing.  
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Supplementary Table 1. Patient demographics 
 
 
 
 Adult 
healthy 
control 
(n=22) 
Child 
healthy 
control 
(n=7) 
Oligo-
arthritis 
 
(n=22) 
Polyarticular 
arthritis 
 
(n=14) 
Enthesitis 
related 
arthritis 
(n=25) 
Psoriatic 
arthritis 
 
(n=10) 
No. male/female 8/14 5/2 10/12 6/8 22/3 2/8 
Age at 
sampling 
(years), median 
(IQR) 
25.99 
(24.93- 
30.19) 
6.29 
(5.48 – 
8.31) 
8.70 
(7 – 11.17) 
10.97 
(9.39 – 12.86) 
14.00 
(12.00 – 
16.46) 
12.32 
(11.20 – 
13) 
Treatment 
received within 
preceding 6 
months of 
sample: MTX 
(%) 
n/a n/a 9/22   
(41%) 
11/14   
(78.57%) 
12/25  
(48%) 
4/10   
(40%) 
Treatment 
received within 
preceding 6 
months of 
sample:  
Biological 
therapy (%) 
n/a n/a 0/22 
(0%) 
3/14  
(21.42%) 
1/25   
(4%) 
2/10 
(20%) 
No. of 
swollen/tender 
joints involved 
at time of 
sampling, 
median (IQR) 
n/a n/a 1  
(1 -2) 
2 
(2 – 3.5) 
2 .50 
(1 -4.5) 
2  
(1.25 – 
4.25) 
ESR mm/hr at 
time of 
sampling, 
median (IQR) 
n/a n/a 25 
(11 – 46) 
41  
(12 – 68) 
19  
(15 - 60) 
30 
(12 – 21) 
HLA-B27+ (%) n/a n/a n/a n/a 21/25  
(84%) 
 
n/a 
RF + (%) n/a n/a n/a 2/14   
(14.28%) 
 
n/a n/a 
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Supplementary Table 2. List of Antibodies for Flow Cytometry and Cell Sorting 
Marker Fluorochrome Clone Supplier 
CD1a PE H149 eBiosciences 
CD3 PE UCHT1 Biolegend 
CD3 V500 UCHT1 BD Biosciences 
CD3 BV605 OKT3 BioLegend 
CD3 BV711 OKT3 BioLegend 
CD4 BV711 OKT4 BioLegend 
CD8a FITC SK1 BD Biosciences 
CD8a APC SK1 eBioscience 
CD11c PE 3.9 BioLegend 
CD14 PE 61D3 BioLegend 
CD16 PE B73.1 eBiosciences 
CD19 PE HIB19 BioLegend 
CD34 PE 561 BioLegend 
CD45 BV421 HI30 BioLegend 
CD45 PE-CY7 HI30 BioLegend 
CD94 PE DX22 BioLegend 
CD123 PE 6H6 BioLegend 
CD127 FITC EBIORDR5 eBiosciences 
CD127 BV711 A019D5 BioLegend 
CD161 APC HP-3G10 eBiosciences 
CD161 BV605 HP-3G10 BioLegend 
CD161 PE-CY7 HP-3G10 eBiosciences 
CD161 BV421 HP-3G10 BioLegend 
CRTH2 FITC BM16 BioLegend 
cKit BV421 104D2 BioLegend 
BDCA2 BV510 1A4 BioLegend 
FcεRIα PE AER-37 BioLegend 
NKp44 APC P44-8 BioLegend 
αβTCR PE IP26 BD Biosciences 
γδTCR PE B1 BD Biosciences 
IL-17AA BV605 BL168 BioLegend 
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Supplementary Table 3. List of primer sequences for PCR 
Gene Primer Sequences 5’- 3’  
Annealing 
Temp (°C)  
ACTB  F AGA TGAC CCAGATCATGTTTGAG  60 
  R  AGGTCCA GACGCAG GATG    
TBX21  F CCCCAAG GAATTGAC AGTTG  60 
  R  GGGAAAC TAAAGCTC ACAAAC    
IFNG  F TGACCAG AGCATCCA AAAGA  60 
  R  CTCTTCGA CCTCGAAA CAGC    
GATA3  F ACCACAAC CACACTCT GGAGGA  60 
  R  TCGGTTTC TGGTCTG GATGCCT    
IL13  F A TTGCTCT CACTTGCC TTGG  60 
  R  GTCAGGTT GATGCTC CATACC    
RORC  F AATCTGGA GCTGGCC TTTCA  60 
  R  CTGGAAG ATCTGCAG CCTTT    
AHR  F CTTAGGCT CAGCGTC AGTTA  60 
  R  GTAAGTTC AGGCCTT CTCTG    
IL17A  F AATCTCCA CCGCAAT GAGGA  60 
  R  ACGTTCCC ATCAGCGT TGA    
IL22  F CCCATCA GCTCCCA CTGC 60 
  R  GGCACCA CCTCCTG CATATA    
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Supplementary Table 4. Uncorrected p values for correlation analyses. 
 
 
Figure X Axis Y Axis Uncorrected 
p Value 
Fig. 2E % of ILC1 within 
total live cells 
Physician’s VAS p=0.0179 
Fig. 2E % of NCR-ILC3 
within total live cells 
Physician’s VAS p=0.0048 
Fig. 2E % of NCR+ILC3 
within total live cells 
Physician’s VAS p=0.0352 
Fig. 2F % of ILC1 within 
total live cells 
Active Joints p=0.4552 
Fig. 2F % of NCR-ILC3 
within total live cells 
Active Joints p=0.0055 
Fig. 2F % of NCR+ILC3 
within total live cells 
Active Joints p=0.8539 
Fig. 2G % of ILC1 within 
total live cells 
ESR (mm/hr) p=0.2307 
Fig. 2G % of NCR-ILC3 
within total live cells 
ESR (mm/hr) p=0.0830 
Fig. 2G % of NCR+ILC3 
within total live cells 
ESR (mm/hr) p=0.1599 
Fig. 3D % of IL-17+ within 
CD4+ T cells 
% of NCR-ILC3 
within total live 
cells 
p=0.0220 
Fig. 3E % of IL-17+ within 
CD8+ T cells 
% of NCR-ILC3 
within total live 
cells 
p=0.0030 
Fig. 3F % of IL-17+ within 
CD4-CD8- T cells 
% of NCR-ILC3 
within total live 
cells 
p=0.0893 
Sup Fig. 2A % of IL-17+ within 
CD4+ T cells 
Physician’s VAS p=0.0114 
Sup Fig. 2A % of IL-17+ within 
CD8+ T cells 
Physician’s VAS p=0.1263 
Sup Fig. 2A % of IL-17+ within 
CD4-CD8- T cells 
Physician’s VAS p=0.8320 
Sup Fig. 2B % of IL-17+ within 
CD4+ T cells 
Active Joints p=0.1117 
Sup Fig. 2B % of IL-17+ within 
CD8+ T cells 
Active Joints p=0.1620 
Sup Fig. 2B % of IL-17+ within 
CD4-CD8- T cells 
Active Joints p=0.5651 
Sup Fig. 2C % of IL-17+ within 
CD4+ T cells 
ESR (mm/hr) p=0.5818 
Sup Fig. 2C % of IL-17+ within 
CD8+ T cells 
ESR (mm/hr) p=0.4069 
Sup Fig. 2C % of IL-17+ within 
CD4-CD8- T cells 
ESR (mm/hr) p=0.9448 
 
P values below 0.0023 are considered statistically significant once corrected with 
Bonferroni’s post-test for multiple testing. 
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